{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:31:39Z","timestamp":1791189099151,"version":"4.1.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1097\/01.wnf.0000220814.48360.f4","type":"journal-article","created":{"date-parts":[[2006,6,12]],"date-time":"2006-06-12T05:22:50Z","timestamp":1150089770000},"page":"148-153","source":"Crossref","is-referenced-by-count":46,"title":["Efficacy and Tolerability of Levetiracetam in Parkinson Disease Patients With Levodopa-Induced Dyskinesia"],"prefix":"10.1097","volume":"29","author":[{"given":"Kelly E.","family":"Lyons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"24","key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease.","volume":"351","author":"Fahn","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice Parameter: treatment of Parkinson's disease with motor fluctuations and dyskinesia(an evidence-based review.) Report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"issue":"11","key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/mds.10542","article-title":"Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by l-dopa and ropinirole in the MPTP-lesioned marmoset.","volume":"18","author":"Hill","year":"2003","journal-title":"Mov Disord"},{"issue":"1","key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.","volume":"310","author":"Hill","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"1-3","key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2003.11.065","article-title":"Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.","volume":"485","author":"Bezard","year":"2004","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents.","volume":"136","author":"Rigo","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"26","key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.wnf.0000157067.50948.2c","article-title":"Levetiracetam in l-dopa-induced dyskinesia.","volume":"28","author":"Meco","year":"2005","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.20563","article-title":"Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.","volume":"20","author":"Zesiewicz","year":"2005","journal-title":"Mov Disord"},{"issue":"5","key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.parkreldis.2004.11.003","article-title":"The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.","volume":"11","author":"Tousi","year":"2005","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-200605000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:34:17Z","timestamp":1785857657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200605000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.wnf.0000220814.48360.f4","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}